Results 161 to 170 of about 75,512 (260)

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto   +12 more
wiley   +1 more source

Editorial: Reviews in hematologic malignancies: 2023

open access: yesFrontiers in Oncology
Billy Michael Chelliah Jebaraj   +2 more
doaj   +1 more source

Safety of Lowering the Platelet Transfusion Threshold Before Central Venous Catheterisation in Patients With Haematological Diseases

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Introduction Central venous catheter (CVC) insertion is frequently required in patients with haematological diseases. Despite limited evidence, thrombocytopenia often prompts prophylactic platelet transfusion before catheterisation. Methods We conducted an observational before‐and‐after study including the first non‐tunnelled CVC insertion ...
Mathias Lazarevic Lindblad   +8 more
wiley   +1 more source

The Immunologic Paradox of BTK Inhibitors in Chronic Lymphocytic Leukemia: Selectivity, Hypogammaglobulinemia, and Infection Risk. [PDF]

open access: yesCancers (Basel)
Andreescu M   +8 more
europepmc   +1 more source

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

open access: yesThe FEBS Journal, EarlyView.
Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma   +1 more
wiley   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

open access: yesThe FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture   +3 more
wiley   +1 more source

Contraceptives in chronic lymphocytic leukemia (CLL): a narrative review. [PDF]

open access: yesAnn Hematol
Al-Shibly R   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy